Abpro, a biotech developing next-generation antibody therapeutics, and the Nanjing,China-based pharma firm NJCTTQ, have entered into an agreement to develop multiple novel bispecific antibody therapies in immuno-oncology, including best-in-class T-cell engagers. The collaboration leverages Abpro’s proprietary DiversImmune antibody discovery platform.   Under the terms of the agreement, Abpro is eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potenti...